Literature DB >> 23049118

Stochastic approximation with virtual observations for dose-finding on discrete levels.

Ying Kuen Cheung1, Mitchell S V Elkind.   

Abstract

Phase I clinical studies are experiments in which a new drug is administered to humans to determine the maximum dose that causes toxicity with a target probability. Phase I dose-finding is often formulated as a quantile estimation problem. For studies with a biological endpoint, it is common to define toxicity by dichotomizing the continuous biomarker expression. In this article, we propose a novel variant of the Robbins-Monro stochastic approximation that utilizes the continuous measurements for quantile estimation. The Robbins-Monro method has seldom seen clinical applications, because it does not perform well for quantile estimation with binary data and it works with a continuum of doses that are generally not available in practice. To address these issues, we formulate the dose-finding problem as root-finding for the mean of a continuous variable, for which the stochastic approximation procedure is efficient. To accommodate the use of discrete doses, we introduce the idea of virtual observation that is defined on a continuous dosage range. Our proposed method inherits the convergence properties of the stochastic approximation algorithm and its computational simplicity. Simulations based on real trial data show that our proposed method improves accuracy compared with the continual re-assessment method and produces results robust to model misspecification.

Entities:  

Year:  2009        PMID: 23049118      PMCID: PMC3412600          DOI: 10.1093/biomet/asp065

Source DB:  PubMed          Journal:  Biometrika        ISSN: 0006-3444            Impact factor:   2.445


  7 in total

1.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

Authors:  Y Lin; W J Shih
Journal:  Biostatistics       Date:  2001-06       Impact factor: 5.899

2.  Non-parametric optimal design in dose finding studies.

Authors:  John O'Quigley; Xavier Paoletti; Jean Maccario
Journal:  Biostatistics       Date:  2002-03       Impact factor: 5.899

3.  A simple technique to evaluate model sensitivity in the continual reassessment method.

Authors:  Ying Kuen Cheung; Rick Chappell
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

Review 4.  Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study.

Authors:  J O'Quigley; S Chevret
Journal:  Stat Med       Date:  1991-11       Impact factor: 2.373

5.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

6.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

7.  The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke.

Authors:  Mitchell S V Elkind; Ralph L Sacco; Robert B MacArthur; Daniel J Fink; Ellinor Peerschke; Howard Andrews; Greg Neils; Josh Stillman; Tania Corporan; Dana Leifer; Ken Cheung
Journal:  Int J Stroke       Date:  2008-08       Impact factor: 5.266

  7 in total
  8 in total

1.  Continual reassessment method with multiple toxicity constraints.

Authors:  Shing M Lee; Bin Cheng; Ying Kuen Cheung
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

2.  Continual Reassessment and Related Dose-Finding Designs.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Sci       Date:  2010       Impact factor: 2.901

3.  Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.

Authors:  Ying Kuen Cheung
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

4.  Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.

Authors:  Laura L Fernandes; Jeremy M G Taylor; Susan Murray
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

5.  On the efficiency of nonparametric variance estimation in sequential dose-finding.

Authors:  Chih-Chi Hu; Ying Kuen Cheung
Journal:  J Stat Plan Inference       Date:  2013-03       Impact factor: 1.111

6.  Multivariate Markov models for the conditional probability of toxicity in phase II trials.

Authors:  Laura L Fernandes; Susan Murray; Jeremy M G Taylor
Journal:  Biom J       Date:  2015-08-07       Impact factor: 2.207

7.  Sample size formulae for the Bayesian continual reassessment method.

Authors:  Ying Kuen Cheung
Journal:  Clin Trials       Date:  2013-08-21       Impact factor: 2.486

8.  A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research.

Authors:  Chunyan Cai; Mohammad H Rahbar; Md Monir Hossain; Ying Yuan; Nicole R Gonzales
Journal:  Contemp Clin Trials Commun       Date:  2017-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.